CATALYST PHARMACEUTICALS, INC.
CPRXCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
vigabatrin
Cocaine Dependence
Amifampridine Phosphate
Lambert Eaton Myasthenic Syndrome
Coagulation Factor IX variant
Hemophilia B
Coagulation Factor VIIa variant
Hemophilia A With Inhibitor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
vigabatrin | Phase 3 | Cocaine Dependence | - | - |
Amifampridine Phosphate | Phase 3 | Lambert Eaton Myasthenic Syndrome | - | - |
Coagulation Factor IX variant | Phase 2 | Hemophilia B | - | - |
Coagulation Factor VIIa variant | Phase 2 | Hemophilia A With Inhibitor | - | - |